Race Oncology Limited (ASX:RAC)

Phillip Lynch
MD & CEO
Market Cap (AUD): 553.72M
Sector: Health Care
Last Trade (AUD): 3.86 +0 (+0%)
Tab Bar

1. About

Race Oncology Limited (ASX:RAC) is a precision oncology company with a Phase II/III cancer drug called Bisantrene.

Bisantrene is a potent inhibitor of the Fat mass and obesity associated (FTO) protein. Over-expression of FTO has been shown to be the driver of a range of different types of cancer.

RAC is exploring the use of Bisantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

RAC also has compelling clinical data for the use of Bisantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.

2. Business model

3. Strategy

4. Markets

5. Competition

6. History

7. Team

8. Financials

9. Risk